ImmunityBio Plans Memory Cytokine-Enriched NK Cell Platform for Solid Tumors

 

• ImmunityBio Inc (NASDAQ: IBRX) has received FDA authorization to conduct a Phase 1 study to evaluate the m-ceNK platform combined with Anktiva (N-803) in locally advanced/metastatic solid tumors.
• Cryopreserved m-ceNK cells combined with Anktiva will be tested in this QUILT 3.076 Phase 1 study designed to evaluate the safety in subjects.
• The study consists of two cohorts, and there will be 10 participants in each cohort. Cohort 1 includes participants with newly diagnosed high-risk solid tumors who have not received prior treatment.
• Cohort 2 includes participants with relapsed/refractory solid tumors who have progressive disease after receiving more than two prior therapies.

https://www.benzinga.com/general/biotech/21/05/21152590/immunitybio-shares-jump-as-it-plans-to-start-testing-memory-cytokine-enriched-nk-cell-platform-in